# A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

> **NCT06143046** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 360 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** mRNA-1345
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06143046
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2026-05-27
- **Final completion:** 2026-05-27
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06143046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06143046, "A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06143046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*